Fig. 7
The in vivo therapeutic efficacy of BsAb-armed T cells. A A schematic showing the schedule of BsAb-armed T cell treatments. Here, 3 × 106 T cells or BsAb-armed T cells were administered intravenously to (50 mm3) bearing SCID mice twice weekly for two weeks (n = 6). Their B tumor size and C body weight were observed. The mice were sacrificed on day 32, and D, E tumors were harvested from each group, weighed, and photographed. F SCID mice bearing established LNCaP (100 mm3) were intravenously injected with 5 × 106 anti-PSMA/anti-CD3 (scFv-Fab) BsAb-armed T cells or OKT3-T cells twice weekly for 2 weeks. The tumors were isolated for IHC staining with anti-CD8 or anti-granzyme B antibodies. The images were taken at 20 × or 40 × magnification. Bar, SD; *p < 0.05; **p < 0.01; ***p < 0.001